PMCB PharmaCyte Biotech
- 2.160
- +0.005+0.23%
PharmaCyte Biotech News
PharmaCyte Biotech | 8-K: Current report
PharmaCyte Biotech | ARS: Annual Report to Security Holders
PharmaCyte Biotech | DEF 14A: Definitive information statements
PharmaCyte Biotech | 10-Q: Quarterly report
PharmaCyte Biotech | SC 13G: Statement of acquisition of beneficial ownership by individuals-Ayrton Capital LLC(9.9%),Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B(9.9%), etc.
PharmaCyte Biotech | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Mitchell P. Kopin(9.99%),Daniel B. Asher(9.99%), etc.
PharmaCyte Biotech: Q2 2024 Earnings Report
PharmaCyte Biotech | 3: Initial statement of beneficial ownership of securities-10% Owner PharmaCyte Biotech, Inc.
PharmaCyte Biotech | 8-K: Current report
PharmaCyte Biotech | 4: Statement of changes in beneficial ownership of securities-Director WEINSTEIN ROBERT
PharmaCyte Biotech | 4: Statement of changes in beneficial ownership of securities-Director WALKER WAYNE REMELL
PharmaCyte Biotech | 4: Statement of changes in beneficial ownership of securities-Chief Financial Officer Trujillo Carlos
PharmaCyte Biotech | 4: Statement of changes in beneficial ownership of securities-Officer Silverman Joshua
PharmaCyte Biotech | 4: Statement of changes in beneficial ownership of securities-Director SCHECHTER JONATHAN
PharmaCyte Biotech | 4: Statement of changes in beneficial ownership of securities-Director Abecassis Michael M
PharmaCyte Biotech | SC 13D: Statement of acquisition of beneficial ownership by individuals-PharmaCyte Biotech, Inc.(37.0%)
PharmaCyte Biotech | 8-K: Current report
PharmaCyte Biotech | 8-K: Current report
PharmaCyte Biotech | EFFECT: Others
PharmaCyte Biotech | CORRESP: CORRESP
Analysis
Price Target
No Data
